-
公开(公告)号：US20210040182A1
公开(公告)日：2021-02-11
申请号：US16836986
申请日：2020-04-01
Applicant: Pfizer Inc.
Abstract: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.
-
公开(公告)号：US10392438B2
公开(公告)日：2019-08-27
申请号：US15309879
申请日：2015-05-13
Applicant: Pfizer Inc.
Inventor： Eric M. Bennett , Nathan Higginson-Scott , Lioudmila Tchistiakova , Kimberly A. Marquette , Janet E. Paulsen , Ruth E. Gimeno
Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.
-
3.发明授权公开(公告)号：US11147852B2
公开(公告)日：2021-10-19
申请号：US14367861
申请日：2012-12-19
Applicant: Pfizer Inc.
Inventor： Kimberly Marquette , Eric Bennett , Lioudmila Tchistiakova , L. Nathan Tumey , Jack Bikker , Valerie Calabro , Edmund Graziani
Abstract: The present invention is directed to antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation. The invention relates to engineered antibody constant region (Fc, Cγ, Cκ, and Cλ) polypeptides, and portions thereof, and antibodies comprising the polypeptides. Further, the invention relates to Fc fusion proteins comprising an engineered Fc region. The invention also relates to methods and uses of the engineered antibodies and portions for, among other things, production of antibody-drug conjugate therapeutics.
-
Patent Agency Ranking
公开(公告)号：US20180179285A1
公开(公告)日：2018-06-28
申请号：US15309879
申请日：2015-05-13
Applicant: Pfizer Inc.
Inventor： Eric M. Bennett , Nathan Higginson-Scott , Lioudmila Tchistiakova , Kimberly A. Marquette , Janet E. Paulsen , Ruth E. Gimeno
CPC classification number: C07K16/2863 , A61P27/16 , C07K16/00 , C07K16/24 , C07K16/244 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/522 , C07K2317/55 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.
-
公开(公告)号：US11578428B2
公开(公告)日：2023-02-14
申请号：US16836986
申请日：2020-04-01
Applicant: Pfizer Inc.
Abstract: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.
-
公开(公告)号：US20170073395A1
公开(公告)日：2017-03-16
申请号：US15155324
申请日：2016-05-16
Applicant: Pfizer Inc.
CPC classification number: C07K16/00 , C07K16/18 , C07K16/40 , C07K16/464 , C07K2317/24 , C07K2317/565 , C07K2317/92 , C07K2317/94
Abstract: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.
Abstract translation: 本文公开了人源化抗体，其中人种系残基引入非人供体抗体的互补决定区（CDR）。 本文还描述了抗体可变结构域（例如，噬菌体展示文库）的文库和用于筛选人源化抗体的方法。
-
7.发明申请Engineered Antibody Constant Regions for Site-Specific Conjugation and Methods and Uses Therefor 审中-公开用于场地特异性缀合的工程抗体恒定区及其方法和用途公开(公告)号：US20160008485A1
公开(公告)日：2016-01-14
申请号：US14367861
申请日：2012-12-19
Applicant: Pfizer Inc.
Inventor： Kimberly Marquette , Eric Bennett , Lioudmila Tchistiakova , L. Nathan Tumey , Jack Bikker , Valerie Calabro , Edmund Graziani
CPC classification number: A61K38/08 , A61K47/6803 , A61K47/6849 , A61K47/6851 , C07K16/00 , C07K16/2863 , C07K16/30 , C07K16/32 , C07K2317/21 , C07K2317/32 , C07K2317/52 , C07K2317/732 , C07K2317/77 , C07K2317/94
Abstract: The present invention is directed to antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation. The invention relates to engineered antibody constant region (Fc, Cγ, Cκ, and Cλ) polypeptides, and portions thereof, and antibodies comprising the polypeptides. Further, the invention relates to Fc fusion proteins comprising an engineered Fc region. The invention also relates to methods and uses of the engineered antibodies and portions for, among other things, production of antibody-drug conjugate therapeutics.
Abstract translation: 本发明涉及针对位点特异性缀合引入氨基酸的抗体及其抗原结合部分。 本发明涉及工程化抗体恒定区（Fc，Cγ，C和kgr，和Cλ）多肽及其部分，以及包含该多肽的抗体。 此外，本发明涉及包含工程化Fc区的Fc融合蛋白。 本发明还涉及工程化抗体的方法和用途，以及除了别的以外产生抗体 - 药物共轭治疗剂的部分。
-
公开(公告)号：US10647756B2
公开(公告)日：2020-05-12
申请号：US15155324
申请日：2016-05-16
Applicant: Pfizer Inc.
Abstract: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.023 seconds)
